Format

Send to

Choose Destination
BMC Cancer. 2010 Oct 11;10:547. doi: 10.1186/1471-2407-10-547.

Low salivary testosterone levels in patients with breast cancer.

Author information

1
DEB, NICHD, NIH, CRC, Room 1-3330, 10 Center Drive, MSC-1103 Bethesda, Maryland, USA. dimitrac@mail.nih.gov

Abstract

BACKGROUND:

Correlation between circulating sex steroid levels and breast cancer has been controversial, with measurement of free, or bioavailable hormone rarely available. Salivary hormone levels represent the bioavailable fraction. To further elucidate the role of endogenous hormones in breast cancer, we aimed to assess correlation between salivary sex steroid levels and breast cancer prevalence.

METHODS:

Salivary hormone levels of testosterone (T), Estradiol (E2), Progesterone (P), Estriol (E3), Estrone (E1), DHEAS and Cortisol (C) were measured by Enzyme Immunoassay (EIA) in 357 women with histologically verified breast cancer and 184 age-matched control women.

RESULTS:

Salivary T and DHEAS levels were significantly lower in breast cancer cases vs. controls (27.2+13.9 vs. 32.2+17.5 pg/ml, p < 0.001 for T and 5.3+4.3 vs. 6.4+4.5 ng/ml, p = 0.007 for DHEAS). E2 and E1 levels were elevated and E3 levels were lowered in cases vs. controls.

CONCLUSIONS:

Salivary T levels, representing the bioavailable hormone, are significantly lower in women with breast cancer compared to age-matched control women. These findings support the protective role of bioavailable testosterone in counteracting the proliferative effects of estrogens on mammary tissue.

PMID:
20937135
PMCID:
PMC2958955
DOI:
10.1186/1471-2407-10-547
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center